Validation of serum biomarkers for detection of early- and late-stage endometrial cancer.
OBJECTIVE
The objective of this study was to determine the efficacy of 3 previously described ovarian cancer serum biomarkers (apolipoprotein-1 [ApoA-I], prealbumin [TTR], transferrin [TF]) in the detection of endometrioid and papillary serous adenocarcinoma of the endometrium.


METHODS
ApoA-I, TTR, and TF levels were measured in serum samples that were obtained from 433 individuals that included 90 women with normal endometrium, 210 women with early-stage endometrial cancer, and 133 women with late-stage endometrial cancer. Multivariate regression models were constructed to evaluate the usefulness of the biomarkers in the detection of endometrial cancer.


RESULTS
ApoA-I, TTR, and TF distinguished normal samples from early-stage endometrial cancer with a sensitivity of 71% (specificity, 88%) and normal samples from late stage endometrial cancer with a sensitivity of 82% (specificity, 86%).


CONCLUSIONS
The biomarker panel that consists of ApoA-I, TTR, and TF may prove to be a useful clinical tool for the detection of endometrial cancer.
Farias-Eisner
Gina
G
Department of Medicine/Cardiology, UCLA, Los Angeles, USA.
Su
Feng
F
Robbins
Terry
T
Kotlerman
Jenny
J
Reddy
Srinivasa
S
Farias-Eisner
Robin
R
D000230:Adenocarcinoma / Q000175:diagnosis*; D018262:Adenocarcinoma, Clear Cell / Q000175:diagnosis; D000328:Adult; D016632:Apolipoprotein A-I / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D016889:Endometrial Neoplasms / Q000175:diagnosis* / Q000473:pathology; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D011228:Prealbumin / Q000032:analysis*; D012044:Regression Analysis; D012680:Sensitivity and Specificity; D014168:Transferrin / Q000032:analysis*
D016632:Apolipoprotein A-I; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D011228:Prealbumin; D014168:Transferrin